• Amine Chemistry Tunes Polymer Micelle mRNA Delivery to Lungs

  2026-06-29

  This study systematically reveals how the chemical structure of amines in polymer micelles determines mRNA binding, in vitro cellular uptake, and in vivo lung targeting. By integrating machine learning with a diverse copolymer library, the authors demonstrate structure-activity relationships critical for optimizing non-viral mRNA delivery vehicles.

• S1P/S1PR3 Axis Drives Neuronal Apoptosis After Intracerebral

  2026-06-28

  This study elucidates how sphingosine-1-phosphate (S1P) promotes neuronal apoptosis via S1PR3 activation of the TNF-α/caspase-3 pathway following acute intracerebral hemorrhage (ICH). The findings highlight S1PR3 as a mechanistically relevant target for neuroprotection in ICH, clarifying a link between S1P signaling, cell death, and neuroinflammation.

• HOBt (1-Hydroxybenzotriazole): Precision in Peptide Synthesi

  2026-06-27

  HOBt (1-Hydroxybenzotriazole) empowers researchers to achieve high-fidelity amide bond formation and effectively minimize epimerization, even with challenging substrates. This article guides you through evidence-based protocols, advanced applications, and practical troubleshooting strategies for leveraging HOBt in modern peptide and small-molecule synthesis.

• Zolmitriptan: Optimized 5-HT1B Receptor Agonist Workflows

  2026-06-26

  Zolmitriptan enables precise modeling of migraine and cluster headache mechanisms through robust, reproducible workflows. This guide translates recent advances in serotonin receptor pharmacology and lysosomal biology into actionable protocols, troubleshooting tactics, and experimental design enhancements.

• Mubritinib (TAK 165) Workflows: Advanced Protocols in Cancer

  2026-06-26

  Mubritinib (TAK 165) empowers researchers to selectively inhibit mitochondrial complex I, unlocking new approaches for chemotherapy-resistant AML and PEL models. Explore validated experimental workflows, troubleshooting tactics, and data-driven protocol enhancements that maximize assay reproducibility and specificity.

• Cdk5 Downregulation Reverses Neuronal Ferroptosis via AMPK P

  2026-06-25

  This study uncovers how inhibiting Cdk5 mitigates ferroptosis in hippocampal neurons by modulating the AMPK pathway and microglial polarization after ischemic stroke. The findings highlight a mechanistic connection between kinase signaling, immune activation, and iron-dependent cell death, with implications for therapeutic targeting of neuroinflammation and iron metabolism.

• Radioiodinated Balsalazide Enables Selective UC Imaging in M

  2026-06-25

  The reference study establishes [131I]balsalazide as a highly selective and stable radiotracer for imaging ulcerative colitis (UC) in murine models. By optimizing radioiodination protocols, the research demonstrates superior colon targeting and biodistribution, offering new possibilities for preclinical UC diagnosis and therapy assessment.

• ECE-1c Stability Drives Stemness and Cisplatin Resistance in

  2026-06-24

  Almarza et al. (2024) demonstrate that stabilization of the ECE-1c isoform in lung cancer cells, via a Lys-6 to Arg mutation, enhances cancer stem cell traits and cisplatin resistance through a CK2 phosphorylation-dependent mechanism. These findings highlight phospho-ECE-1c as a potential prognostic biomarker and support CK2 inhibition as a promising strategy in non–small cell lung cancer (NSCLC) therapy.

• FerroOrange Fe²⁺ Fluorescent Probe: Live-Cell Iron Detection

  2026-06-23

  FerroOrange enables precise, real-time visualization of intracellular Fe²⁺ in living cells—empowering robust exploration of iron metabolism and ferroptosis. This guide details applied workflows, advanced troubleshooting, and key innovations for optimizing your Fe²⁺ fluorescent probe assays.

• Optimizing Cell Assays with Recombinant Human EGF

  2026-06-23

  Recombinant human EGF, expressed in E. coli, streamlines cell proliferation and mucosal healing workflows with unmatched purity and reproducibility. This article delivers actionable protocols, troubleshooting strategies, and advanced experimental insights that empower researchers to unlock the full potential of EGF in cell culture and oncology.

• CD28-ARS2 Axis Drives PKM Splicing and Metabolic Flexibility

  2026-06-22

  This study reveals that the CD28-ARS2 signaling axis orchestrates alternative splicing of the pyruvate kinase gene (PKM), enabling metabolic flexibility and robust antitumor function in CD8+ T cells. The findings provide mechanistic insight into how T cell activation rewires metabolism beyond canonical signaling pathways, with implications for immunotherapy design.

• Indomethacin in Inflammation Research: Protocols & Innovatio

  2026-06-22

  Indomethacin’s unique Cox-1 selectivity and PPARγ agonism make it a crucial tool for dissecting inflammation, lipid metabolism, and membrane signaling pathways. This article delivers enhanced protocols, troubleshooting insights, and bridges recent mechanistic studies to practical bench workflows, helping researchers maximize reproducibility and experimental clarity.

• CX-5461: RNA Polymerase I Inhibitor Workflows in Cancer Rese

  2026-06-21

  CX-5461, a potent RNA polymerase I inhibitor, is transforming cancer research by enabling precise modulation of ribosome biogenesis and uncovering new strategies for targeting solid tumor growth and chemoresistance. This article provides actionable workflows, troubleshooting guidance, and contextualizes the latest breakthroughs for advanced users.

• Single-Cell ERK Dynamics Reveal EGFR's Role in Mutant CRC Si

  2026-06-20

  This study utilizes patient-derived colorectal cancer organoids and an advanced FRET-based biosensor to quantify ERK dynamics at the single-cell level. The findings demonstrate that EGFR activity amplifies oncogenic MAPK pathway signaling in KRAS and BRAF mutant tumors, providing mechanistic insight into why combined EGFR and MAPK inhibition is more effective than targeting the pathway alone.

• CLK2 Drives Platinum Resistance in Ovarian Cancer via BRCA1

  2026-06-19

  This study reveals that Cdc2-like kinase 2 (CLK2) confers platinum resistance in ovarian cancer by phosphorylating BRCA1, enhancing DNA repair and impairing chemotherapeutic efficacy. These mechanistic insights suggest CLK2 as a promising therapeutic target for overcoming resistance in BRCA-associated cancer therapy.

465 records 14/31 page Previous Next First page 上5页 1112131415 下5页 Last page